<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05073640</url>
  </required_header>
  <id_info>
    <org_study_id>03-019-MZR</org_study_id>
    <nct_id>NCT05073640</nct_id>
  </id_info>
  <brief_title>Pentoxifylline Add-on Therapy for Schizophrenia</brief_title>
  <official_title>Pentoxifylline Add-on Therapy for Schizophrenia: A Randomized, Placebo-controlled, Double-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mazra Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ben-Gurion University of the Negev</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mazra Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The etiology and pathogenesis of schizophrenia remain unclear. The immune dysfunction&#xD;
      hypothesis for schizophrenia has attracted increasing attention from researchers, and&#xD;
      substantial evidence suggested that the levels of TNF-α and other cytokines are markedly&#xD;
      elevated in patients with schizophrenia. The investigators aim to evaluate the adjuvant&#xD;
      therapeutic effect of Pentoxifylline, a TNF-α inhibitor that crosses the blood-brain barrier,&#xD;
      in a randomized, double-blind, 6-week trial. Individuals with schizophrenia will receive&#xD;
      either Pentoxifylline or a matching placebo as an add-on treatment to antipsychotic agents.&#xD;
      Subjects' positive and negative symptoms and plasma concentration of neuroinflammatory&#xD;
      markers will be monitored at baseline and every two weeks until the end of the trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ninety schizophrenic patients will be randomized to a Pentoxifylline (400 mg twice a day) or&#xD;
      placebo treatment for six weeks. Pentoxifylline and placebo will be added to the current&#xD;
      antipsychotic drug treatment. Participants will be asked to fill a socio-demographic&#xD;
      questionnaire and to undergo a clinical differential diagnosis using the Symptoms Check List&#xD;
      (SCL)-90, Clinical Global Impression (CGI), positive and negative symptoms scale (PANSS), and&#xD;
      Hamilton depression rating scale (HAM-D). Following baseline evaluation, participants will be&#xD;
      monitored for symptoms every two weeks until the end of the trial (overall three visits)&#xD;
      using CGI, PANSS, and HAM-D. Adverse effects will be documented every visit using the&#xD;
      Treatment Emergent Symptom Scale. Finally, yet importantly, a blood sample will be collected&#xD;
      at baseline and every two weeks until the end of the trial to study the treatment effect on&#xD;
      inflammatory markers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and negative symptoms</measure>
    <time_frame>Subjects will be monitored at baseline and every two weeks for six weeks</time_frame>
    <description>Improvement in positive and negative symptoms (Changes in PANSS rates)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms</measure>
    <time_frame>Subjects will be monitored at baseline and every two weeks for six weeks</time_frame>
    <description>Changes in HAM-D rates</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pentoxifylline (Oxopurin 400 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (105 mg Lactose and 510 mg Dextrose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxopurin</intervention_name>
    <description>Subjects will receive two capsules per day.</description>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Pentoxifylline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients meeting the DSM-V criteria for schizophrenia spectrum disorders.&#xD;
&#xD;
          2. Clinical Global Impression (CGI) score ≥ 4 and ≤ 6 at screening.&#xD;
&#xD;
          3. Initiated treatment with a stable dosage of typical and/or atypical antipsychotic&#xD;
             medication for at least four weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous sensitivity to pentoxifylline (PTF).&#xD;
&#xD;
          2. Chronic immune and/or inflammatory diseases (such as rheumatoid arthritis, systemic&#xD;
             lupus erythematosus, chronic inflammatory bowel disease).&#xD;
&#xD;
          3. Consumption for &gt; 3 consecutive days of any immune-modulating or anti-inflammatory&#xD;
             drug in the last month.&#xD;
&#xD;
          4. Current active and persistent substance and/or alcohol abuse.&#xD;
&#xD;
          5. Any severe, unstable medical condition (e.g., cardiovascular disorders, diabetes&#xD;
             mellitus, respiratory diseases, cancer).&#xD;
&#xD;
          6. Obesity (body mass index &gt; 30).&#xD;
&#xD;
          7. Cognitive dysfunction such as retardation.&#xD;
&#xD;
          8. Known or suspected pregnancy or breastfeeding women.&#xD;
&#xD;
          9. Lactose intolerance or sensitivity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alon Shamir, Ph.D.</last_name>
    <phone>+97249954708</phone>
    <email>alons@mazor.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mazor MHC</name>
      <address>
        <city>Akko</city>
        <zip>25201</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alon Shamir, Ph.D</last_name>
      <phone>+97249954708</phone>
      <email>alons@mazor.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

